 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | BI 706321 / Boehringer Ingelheim
Enrollment closed: A Study to Test Whether BI 706321 Combined With Ustekinumab Helps People With Crohn's Disease (clinicaltrials.gov) - Apr 16, 2024
P2, N=49, Active, not recruiting, Sponsor: Boehringer Ingelheim
Recruiting --> Active, not recruiting
- || BI 706321 / Boehringer Ingelheim
Trial completion date, Trial primary completion date: A Study in Healthy Japanese and Chinese Men to Test How Well Different Doses of BI 706321 Are Tolerated (clinicaltrials.gov) - Apr 4, 2024
P1, N=60, Recruiting, Sponsor: Boehringer Ingelheim
Recruiting --> Active, not recruiting Trial completion date: Feb 2025 --> Oct 2025 | Trial primary completion date: Feb 2025 --> Oct 2025
- BI 706321 / Boehringer Ingelheim
Phase classification: A Study to Test Whether BI 706321 Combined With Ustekinumab Helps People With Crohn's Disease (clinicaltrials.gov) - Dec 13, 2023
P2, N=50, Recruiting, Sponsor: Boehringer Ingelheim
Trial completion date: Feb 2025 --> Oct 2025 | Trial primary completion date: Feb 2025 --> Oct 2025 Phase classification: P2a --> P2
- || BI 706321 / Boehringer Ingelheim
Trial completion date, Trial primary completion date: A Study in Healthy Japanese and Chinese Men to Test How Well Different Doses of BI 706321 Are Tolerated (clinicaltrials.gov) - Jul 5, 2023
P1, N=60, Recruiting, Sponsor: Boehringer Ingelheim
Phase classification: P2a --> P2 Trial completion date: Oct 2024 --> Feb 2025 | Trial primary completion date: Oct 2024 --> Feb 2025
- | BI 706321 / Boehringer Ingelheim
Trial completion date, Trial primary completion date: A Study to Test Whether BI 706321 Combined With Ustekinumab Helps People With Crohn's Disease (clinicaltrials.gov) - May 31, 2023
P2a, N=50, Recruiting, Sponsor: Boehringer Ingelheim
Trial completion date: Oct 2024 --> Feb 2025 | Trial primary completion date: Oct 2024 --> Feb 2025 Trial completion date: Nov 2024 --> Mar 2025 | Trial primary completion date: Mar 2024 --> Jun 2024
- || BI 706321 / Boehringer Ingelheim
Trial completion date, Trial primary completion date: A Study in Healthy Japanese and Chinese Men to Test How Well Different Doses of BI 706321 Are Tolerated (clinicaltrials.gov) - Feb 28, 2023
P1, N=60, Recruiting, Sponsor: Boehringer Ingelheim
Trial completion date: Nov 2024 --> Mar 2025 | Trial primary completion date: Mar 2024 --> Jun 2024 Trial completion date: Feb 2024 --> Oct 2024 | Trial primary completion date: Feb 2024 --> Oct 2024
- ||| BI 706321 / Boehringer Ingelheim
Enrollment open: A Study in Healthy Japanese and Chinese Men to Test How Well Different Doses of BI 706321 Are Tolerated (clinicaltrials.gov) - Jan 25, 2023
P1, N=60, Recruiting, Sponsor: Boehringer Ingelheim
Trial completion date: Feb 2024 --> Oct 2024 | Trial primary completion date: Feb 2024 --> Oct 2024 Active, not recruiting --> Recruiting
- | BI 706321 / Boehringer Ingelheim
Trial completion date, Trial primary completion date: A Study to Test Whether BI 706321 Combined With Ustekinumab Helps People With Crohn's Disease (clinicaltrials.gov) - Nov 29, 2022
P2a, N=50, Recruiting, Sponsor: Boehringer Ingelheim
Active, not recruiting --> Recruiting Trial completion date: Feb 2024 --> Nov 2024 | Trial primary completion date: Jun 2023 --> Mar 2024
- || BI 706321 / Boehringer Ingelheim
Enrollment closed: A Study in Healthy Japanese and Chinese Men to Test How Well Different Doses of BI 706321 Are Tolerated (clinicaltrials.gov) - Oct 12, 2022
P1, N=48, Active, not recruiting, Sponsor: Boehringer Ingelheim
Trial completion date: Feb 2024 --> Nov 2024 | Trial primary completion date: Jun 2023 --> Mar 2024 Recruiting --> Active, not recruiting
- || BI 706321 / Boehringer Ingelheim
Trial completion date, Trial primary completion date: A Study in Healthy Japanese and Chinese Men to Test How Well Different Doses of BI 706321 Are Tolerated (clinicaltrials.gov) - Sep 7, 2022
P1, N=60, Recruiting, Sponsor: Boehringer Ingelheim
Recruiting --> Active, not recruiting Trial completion date: Jun 2023 --> Feb 2024 | Trial primary completion date: Jun 2023 --> Feb 2024
- | BI 706321 / Boehringer Ingelheim
Trial completion date, Trial primary completion date: A Study to Test Whether BI 706321 Combined With Ustekinumab Helps People With Crohn's Disease (clinicaltrials.gov) - Jun 28, 2022
P2a, N=50, Recruiting, Sponsor: Boehringer Ingelheim
Trial completion date: Jun 2023 --> Feb 2024 | Trial primary completion date: Jun 2023 --> Feb 2024 Trial completion date: Aug 2023 --> Feb 2024 | Trial primary completion date: Nov 2022 --> Jun 2023
- || BI 706321 / Boehringer Ingelheim
Trial completion date, Trial primary completion date: A Study in Healthy Japanese and Chinese Men to Test How Well Different Doses of BI 706321 Are Tolerated (clinicaltrials.gov) - Feb 25, 2022
P1, N=60, Recruiting, Sponsor: Boehringer Ingelheim
Trial completion date: Aug 2023 --> Feb 2024 | Trial primary completion date: Nov 2022 --> Jun 2023 Trial completion date: Sep 2022 --> Jul 2023 | Trial primary completion date: Sep 2022 --> Jun 2023
- ||| BI 706321 / Boehringer Ingelheim
Enrollment open: A Study in Healthy Japanese and Chinese Men to Test How Well Different Doses of BI 706321 Are Tolerated (clinicaltrials.gov) - Feb 9, 2022
P1, N=60, Recruiting, Sponsor: Boehringer Ingelheim
Trial completion date: Sep 2022 --> Jul 2023 | Trial primary completion date: Sep 2022 --> Jun 2023 Not yet recruiting --> Recruiting
- ||| BI 706321 / Boehringer Ingelheim
New P1 trial: A Study in Healthy Japanese and Chinese Men to Test How Well Different Doses of BI 706321 Are Tolerated (clinicaltrials.gov) - Jan 9, 2022
P1, N=60, Not yet recruiting, Sponsor: Boehringer Ingelheim
- | BI 706321 / Boehringer Ingelheim
Trial completion date, Trial primary completion date: A Study to Test Whether BI 706321 Combined With Ustekinumab Helps People With Crohn's Disease (clinicaltrials.gov) - Dec 3, 2021
P2a, N=50, Recruiting, Sponsor: Boehringer Ingelheim
Not yet recruiting --> Recruiting Trial completion date: Mar 2023 --> Jul 2023 | Trial primary completion date: Jul 2022 --> Nov 2022
- || BI 706321 / Boehringer Ingelheim
Enrollment open: A Study to Test Whether BI 706321 Combined With Ustekinumab Helps People With Crohn's Disease (clinicaltrials.gov) - Nov 8, 2021
P2a, N=50, Recruiting, Sponsor: Boehringer Ingelheim
Trial completion date: Mar 2023 --> Jul 2023 | Trial primary completion date: Jul 2022 --> Nov 2022 Not yet recruiting --> Recruiting
- || BI 706321 / Boehringer Ingelheim
New P2a trial: A Study to Test Whether BI 706321 Combined With Ustekinumab Helps People With Crohn's Disease (clinicaltrials.gov) - Jul 27, 2021
P2a, N=50, Not yet recruiting, Sponsor: Boehringer Ingelheim
- || BI 706321 / Boehringer Ingelheim
Trial completion: A Study in Healthy Men to Test How Itraconazole Influences the Amount of BI 706321 in the Blood (clinicaltrials.gov) - May 5, 2021
P1, N=14, Completed, Sponsor: Boehringer Ingelheim
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- || BI 706321 / Boehringer Ingelheim
Enrollment closed: A Study in Healthy Men to Test How Itraconazole Influences the Amount of BI 706321 in the Blood (clinicaltrials.gov) - Mar 26, 2021
P1, N=14, Active, not recruiting, Sponsor: Boehringer Ingelheim
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- || BI 706321 / Boehringer Ingelheim
Enrollment open: A Study in Healthy Men to Test How Itraconazole Influences the Amount of BI 706321 in the Blood (clinicaltrials.gov) - Feb 11, 2021
P1, N=14, Recruiting, Sponsor: Boehringer Ingelheim
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- || BI 706321 / Boehringer Ingelheim
New P1 trial: A Study in Healthy Men to Test How Itraconazole Influences the Amount of BI 706321 in the Blood (clinicaltrials.gov) - Jan 18, 2021
P1, N=14, Not yet recruiting, Sponsor: Boehringer Ingelheim
- || BI 706321 / Boehringer Ingelheim
Trial completion: A Study to Test How Well Healthy Men and Women Tolerate Different Doses of BI 706321 (clinicaltrials.gov) - Jan 12, 2021
P1, N=39, Completed, Sponsor: Boehringer Ingelheim
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||| BI 706321 / Boehringer Ingelheim
Trial completion: A Study to Test How Well Healthy Men Tolerate Different Doses of BI 706321 (clinicaltrials.gov) - Dec 10, 2020
P1, N=61, Completed, Sponsor: Boehringer Ingelheim
Active, not recruiting --> Completed Active, not recruiting --> Completed
- || BI 706321 / Boehringer Ingelheim
Enrollment closed, Enrollment change: A Study to Test How Well Healthy Men and Women Tolerate Different Doses of BI 706321 (clinicaltrials.gov) - Nov 19, 2020
P1, N=39, Active, not recruiting, Sponsor: Boehringer Ingelheim
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | N=60 --> 39
- || BI 706321 / Boehringer Ingelheim
Enrollment closed, Trial completion date, Trial primary completion date: A Study to Test How Well Healthy Men Tolerate Different Doses of BI 706321 (clinicaltrials.gov) - Aug 11, 2020
P1, N=61, Active, not recruiting, Sponsor: Boehringer Ingelheim
Recruiting --> Active, not recruiting | N=60 --> 39 Suspended --> Active, not recruiting | Trial completion date: Jul 2020 --> Oct 2020 | Trial primary completion date: Jul 2020 --> Oct 2020
- ||| BI 706321 / Boehringer Ingelheim
Enrollment open: A Study to Test How Well Healthy Men and Women Tolerate Different Doses of BI 706321 (clinicaltrials.gov) - Jun 25, 2020
P1, N=60, Recruiting, Sponsor: Boehringer Ingelheim
Suspended --> Active, not recruiting | Trial completion date: Jul 2020 --> Oct 2020 | Trial primary completion date: Jul 2020 --> Oct 2020 Suspended --> Recruiting
- |||| BI 706321 / Boehringer Ingelheim
Trial suspension: A Study to Test How Well Healthy Men and Women Tolerate Different Doses of BI 706321 (clinicaltrials.gov) - Apr 6, 2020
P1, N=60, Suspended, Sponsor: Boehringer Ingelheim
Suspended --> Recruiting Recruiting --> Suspended
- | BI 706321 / Boehringer Ingelheim
Enrollment change, Trial suspension: A Study to Test How Well Healthy Men Tolerate Different Doses of BI 706321 (clinicaltrials.gov) - Apr 5, 2020
P1, N=80, Suspended, Sponsor: Boehringer Ingelheim
Recruiting --> Suspended N=61 --> 80 | Active, not recruiting --> Suspended
- ||| BI 706321 / Boehringer Ingelheim
Enrollment open: A Study to Test How Well Healthy Men and Women Tolerate Different Doses of BI 706321 (clinicaltrials.gov) - Feb 5, 2020
P1, N=60, Recruiting, Sponsor: Boehringer Ingelheim
N=61 --> 80 | Active, not recruiting --> Suspended Not yet recruiting --> Recruiting
- ||| BI 706321 / Boehringer Ingelheim
New P1 trial: A Study to Test How Well Healthy Men and Women Tolerate Different Doses of BI 706321 (clinicaltrials.gov) - Jan 27, 2020
P1, N=60, Not yet recruiting, Sponsor: Boehringer Ingelheim
- || BI 706321 / Boehringer Ingelheim
Enrollment change: A Study to Test How Well Healthy Men Tolerate Different Doses of BI 706321 (clinicaltrials.gov) - Dec 22, 2019
P1, N=61, Active, not recruiting, Sponsor: Boehringer Ingelheim
Not yet recruiting --> Recruiting N=46 --> 61
- | BI 706321 / Boehringer Ingelheim
Enrollment closed, Enrollment change: A Study to Test How Well Healthy Men Tolerate Different Doses of BI 706321 (clinicaltrials.gov) - Oct 16, 2019
P1, N=46, Active, not recruiting, Sponsor: Boehringer Ingelheim
N=46 --> 61 Recruiting --> Active, not recruiting | N=80 --> 46
- | BI 706321 / Boehringer Ingelheim
Trial completion date, Trial primary completion date: A Study to Test How Well Healthy Men Tolerate Different Doses of BI 706321 (clinicaltrials.gov) - Oct 15, 2019
P1, N=80, Recruiting, Sponsor: Boehringer Ingelheim
Recruiting --> Active, not recruiting | N=80 --> 46 Trial completion date: Oct 2019 --> Apr 2020 | Trial primary completion date: Oct 2019 --> Apr 2020
- ||| BI 706321 / Boehringer Ingelheim
Enrollment open: A Study to Test How Well Healthy Men Tolerate Different Doses of BI 706321 (clinicaltrials.gov) - Jul 5, 2019
P1, N=80, Recruiting, Sponsor: Boehringer Ingelheim
Trial completion date: Oct 2019 --> Apr 2020 | Trial primary completion date: Oct 2019 --> Apr 2020 Not yet recruiting --> Recruiting
- ||| BI 706321 / Boehringer Ingelheim
New P1 trial: A Study to Test How Well Healthy Men Tolerate Different Doses of BI 706321 (clinicaltrials.gov) - Jun 2, 2019
P1, N=80, Not yet recruiting, Sponsor: Boehringer Ingelheim